Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease

2021 ◽  
pp. 257-272
Author(s):  
Luis E. Simental-Mendía ◽  
Claudia I. Gamboa-Gómez ◽  
Fernando Guerrero-Romero ◽  
Mario Simental-Mendía ◽  
Adriana Sánchez-García ◽  
...  
Keyword(s):  
Natural Products ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease

scholarly journals Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease

2018 ◽  
Vol 37 (1) ◽  
pp. 63-68 ◽  
Author(s):  
Roger F. Butterworth ◽  
Ali Canbay
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Preliminary Report ◽  
Liver Enzymes ◽  
Hepatic Microcirculation ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Anti Oxidant ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited. Summary: L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of a multicenter randomized clinical trial reveal that 12 weeks treatment with oral LOLA (6–9 g/d) results in a dose-related reduction in activities of liver enzymes and triglycerides together with significant improvements of liver/spleen CT ratios. A preliminary report described improvements of hepatic microcirculation in patients with non-alcoholic steatohepatitis (NASH) following treatment with LOLA. Mechanisms responsible for the beneficial effects of LOLA in NAFLD/NASH involve, in addition to its established ammonia-lowering effect, metabolic transformations of the LOLA-constituent amino acids L-ornithine and L-aspartate into L-glutamine, L-arginine, and glutathione. These metabolites have well-established actions implicated in the prevention of lipid peroxidation, improvement of hepatic microcirculation in addition to anti-inflammatory, and anti-oxidant properties. Key Messages: (1) LOLA is effective for the treatment of key indices in NAFLD/NASH. (2) Mechanisms other than LOLA’s ammonia-lowering action have been postulated. (3) Further assessments in the clinical setting are now required.

scholarly journals Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies

2021 ◽  
Vol 10 (17) ◽  
pp. 3783
Author(s):  
Julie Steen Pedersen ◽  
Marte Opseth Rygg ◽  
Reza Rafiolsadat Serizawa ◽  
Viggo Bjerregaard Kristiansen ◽  
Nicolai J. Wewer Albrechtsen ◽  
...  
Keyword(s):  
Gastric Bypass ◽  
Sleeve Gastrectomy ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Plasma Lipid ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease

Roux-en-Y gastric bypass (RYGB) improves, and can sometimes resolve, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) but data based on histological assessment for the efficacy of sleeve gastrectomy (SG) in resolving NAFLD are sparse. Consequently, we aimed to compare the efficacy of RYGB vs. SG on NAFLD 12 months after surgery. In a prospective cohort study, 40 patients with obesity underwent bariatric surgery (16 RYGB and 24 SG). During surgery, a liver biopsy was taken and repeated 12 months later. NAFLD severity was evaluated using the NAFLD Activity Score (NAS) and Kleiner Fibrosis score. RYGB and SG patients were comparable at baseline. Mean (standard deviation, SD) NAS was 3.3 (0.9) in RYGB and 3.1 (1.4) in SG (p = 0.560) with similar degrees of steatosis, inflammation, and ballooning. Two RYGB patients, and six SG patients, had NASH (p = 0.439). Twelve months after surgery, NAS was significantly and comparably (p = 0.241) reduced in both RYGB (−3.00 (95% CI −3.79–−2.21), p < 0.001) and SG (−2.25 (95% CI −2.92–−1.59), p < 0.001) patients. RYGB patients had significantly more reduced (p = 0.007) liver steatosis (−0.91 (95% CI −1.47–−1.2) than SG patients (−0.33 (95% CI −0.54–−0.13) and greater improvement in the plasma lipid profile. Fibrosis declined non-significantly. NASH was resolved in seven of eight patients without a worsening of their fibrosis. RYGB and SG have similar beneficial effects on NAS and NASH without the worsening of fibrosis. RYGB is associated with a more pronounced reduction in liver steatosis.

scholarly journals Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease

2019 ◽  
Vol 12 (5) ◽  
pp. dmm039206 ◽  
Author(s):  
Sara Carbajo-Pescador ◽  
David Porras ◽  
María Victoria García-Mediavilla ◽  
Susana Martínez-Flórez ◽  
María Juarez-Fernández ◽  
...  
Keyword(s):  
Liver Disease ◽  
Gut Microbiota ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
In Vivo Model ◽  
Alcoholic Fatty Liver ◽  
Barrier Integrity ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease

The Beneficial Effects of Silymarin in Treatment of Experimentally Induced Non-Alcoholic Fatty Liver Disease in Rats

2018 ◽  
Vol 86 (3) ◽  
pp. 1055-1064
Author(s):  
HEBAT ALLAH M. MAHMOUD, M.Sc.; FATMA A. MAHMOUD, M.D. ◽  
GHADA HASHEM, M.D.; HANAN H. AHMED, M.D. ◽  
HESHAM M. MAHMOUD, M.D.
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Beneficial Effects ◽  
Alcoholic Fatty Liver Disease ◽  
Experimentally Induced

scholarly journals SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Kwang-Youn Kim ◽  
Hyun-Jun Jang ◽  
Yong Ryoul Yang ◽  
Kwang-Il Park ◽  
JeongKon Seo ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
High Fat Diet ◽  
Fatty Liver Disease ◽  
Hepatic Triglyceride ◽  
Alcoholic Fatty Liver ◽  
Over Expression ◽  
Beneficial Effects ◽  
Triglyceride Accumulation ◽  
Alcoholic Fatty Liver Disease

Abstract Dysregulated autophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), however the mechanisms connecting them remain poorly understand. Here, we show that co-administration of lovastatin and ezetimibe (L/E) significantly reverses hepatic triglyceride accumulation concomitant with an increase in SREBP-2 driven autophagy in mice fed a high-fat diet (HFD). We further show that the statin mediated increase in SREBP-2 directly activates expression of patatin-like phospholipase domain-containing enzyme 8 (PNPLA8) gene, and PNPLA8 associates with autophagosomes and is associated with a decrease in cellular triglyceride. Moreover, we show that over-expression of PNPLA8 dramatically decreases hepatic steatosis through increased autophagy in hepatocytes of HFD-fed mice. Live-cell imaging analyses also reveal that PNPLA8 dynamically interacts with LC3 and we suggest that the SREBP-2/PNPLA8 axis represents a novel regulatory mechanism for lipid homeostasis. These data provide a possible mechanism for the reported beneficial effects of statins for decreasing hepatic triglyceride levels in NAFLD patients.

Sign in / Sign up

Export Citation Format

Share Document